FDA Moves to Register Overseas Tobacco Makers
Published Date: 6/29/2026
Proposed Rule
Summary
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
Analyzed Economic Effects
7 provisions identified: 1 benefits, 6 costs, 0 mixed.
Foreign Makers Must Register and List
If finalized, owners and operators of foreign establishments that manufacture, prepare, compound, or process tobacco products sold in or offered for import into the United States would have to register their establishments and list their products with FDA. The proposal explicitly extends current registration and listing requirements to foreign establishments under proposed 21 CFR 1108 and would bring parity between domestic and foreign owners/operators.
Foreign Establishments Subject to FDA Inspections
The proposal would make registered foreign establishments subject to FDA inspections under sections 905(g) and 905(h) of the FD&C Act. FDA states that registered foreign establishments would be subject to inspection in support of enforcement and premarket review activities.
More Entities Count as 'Manufacturers'
The proposed rule clarifies that the term 'manufacture' includes specification developers, third-party manufacturers, bulk tobacco product manufacturers, and repackagers/relabelers. As a result, these types of entities would be required to register and list products under the proposed 21 CFR 1108 requirements.
Noncompliance Can Trigger Enforcement Actions
The document states that failure to register, to provide required product listing information, or to provide required notices can constitute prohibited acts under section 301 of the FD&C Act and that violations related to establishment registration and product listing are subject to regulatory action, including civil money penalties, seizure, and injunction.
Electronic Submission Required (Waivers Possible)
The proposed rule would generally require electronic submission of establishment registration and tobacco product listing information, unless FDA grants a waiver. FDA says electronic submission would be used by all registrants and would further the Government Paperwork Elimination Act goals.
New Recordkeeping Requirements for Listed Products
The proposed rule would require owners or operators to maintain a historical file of consumer information, labeling, and advertisements for all tobacco products listed, and to keep records about the distribution of free samples of smokeless tobacco products. These recordkeeping requirements are proposed under sections 905 and 909 of the FD&C Act.
Agency Estimates of Annualized Costs
FDA estimates 20-year annualized total costs to domestic and foreign establishments and FDA would range from $6.80 million to $26.55 million, with a primary estimate of $15.57 million at a 7% discount rate. FDA reports domestic-establishment costs of $0.013 million (primary estimate) and foreign-establishment costs of $0.37 million (primary estimate), with FDA shouldering about 97.5% of total costs in the primary estimate.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-12884 — Agency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Products
The FDA wants your thoughts on how they collect info about nonprescription drug applications, especially about timing and usage. This affects drug makers and anyone interested in over-the-counter meds. You’ve got until August 25, 2026, to share your comments—no fees, just your voice helping shape the process!
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12937 — List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
The FDA is giving folks more time to share their thoughts on whether certain medicines like semaglutide, tirzepatide, and liraglutide should be allowed for special compounding by outsourcing drug makers. This extension means anyone interested has until July 30, 2026, to weigh in. It affects drug makers, healthcare pros, and patients waiting for these meds, with no immediate cost changes but plenty of chances to influence future drug availability.
Previous / Next Documents
Previous: 2026-13034 — Airworthiness Directives; Airbus Helicopters Deutschland GmbH (AHD) Helicopters
If you own or operate certain Airbus Helicopters Deutschland models, listen up! The FAA wants you to regularly check your tail rotor blades for cracks caused by corrosion and replace any damaged parts to keep flying safe. Comments on this new rule are open until August 13, 2026, so get ready to inspect and possibly spend some bucks to keep your chopper in top shape.
Next: 2026-13054 — Fisheries Off West Coast States; Coastal Pelagic Species Fisheries; Annual Specifications; 2026-2027 Annual Specifications and Management Measures for Pacific Sardine
Starting July 1, 2026, most commercial fishing for Pacific sardines off Washington, Oregon, and California will be paused to help the sardine population bounce back. Only limited fishing for live bait, small catches, or special permits will be allowed. This plan sets clear catch limits to protect the fish and supports a healthier ocean and fishing future.